JP2016540503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540503A5 JP2016540503A5 JP2016532031A JP2016532031A JP2016540503A5 JP 2016540503 A5 JP2016540503 A5 JP 2016540503A5 JP 2016532031 A JP2016532031 A JP 2016532031A JP 2016532031 A JP2016532031 A JP 2016532031A JP 2016540503 A5 JP2016540503 A5 JP 2016540503A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody polypeptide
- antibody
- seq
- emitters
- polypeptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 30
- 108090001123 antibodies Proteins 0.000 claims 30
- 229920001184 polypeptide Polymers 0.000 claims 28
- 206010060862 Prostate cancer Diseases 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000001809 detectable Effects 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 230000001225 therapeutic Effects 0.000 claims 3
- 229960000958 Deferoxamine Drugs 0.000 claims 2
- 206010027476 Metastasis Diseases 0.000 claims 2
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 2
- 210000004197 Pelvis Anatomy 0.000 claims 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 230000001394 metastastic Effects 0.000 claims 2
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical class OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 101700063989 GILX Proteins 0.000 claims 1
- 102000018297 Immunoglobulin subtype Human genes 0.000 claims 1
- 108050007411 Immunoglobulin subtype Proteins 0.000 claims 1
- 101700035575 KLK2 Proteins 0.000 claims 1
- 102100011335 KLK2 Human genes 0.000 claims 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 229960003330 Pentetic Acid Drugs 0.000 claims 1
- 210000000664 Rectum Anatomy 0.000 claims 1
- 210000003932 Urinary Bladder Anatomy 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 230000001472 cytotoxic Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000007915 intraurethral administration Methods 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Claims (24)
- ヒトカリクレイン−2(hK2)に対する結合特異性を持つ抗体ポリペプチドであって、前記抗体ポリペプチドは:
(a)配列番号8のアミノ酸配列を含むまたはそれからなる重鎖可変領域;および
(b)配列番号9のアミノ酸配列を含むまたはそれからなる軽鎖可変領域;
を含む、前記抗体ポリペプチド。 - 完全な抗体、またはFvフラグメント、Fab様フラグメント、およびドメイン抗体からなる群から選択される抗原結合フラグメント、を含むまたはそれからなる、請求項1に記載の抗体ポリペプチド。
- 重鎖定常領域またはその部分をさらに含み、前記重鎖定常領域は、IgG1、IgG2、IgG3およびIgG4からなる群から選択される免疫グロブリンサブタイプのものである、請求項1または2に記載の抗体ポリペプチド。
- 軽鎖定常領域またはその部分をさらに含み、前記軽鎖定常領域は、κまたはλ軽鎖のものである、請求項1〜3のいずれか1項に記載の抗体ポリペプチド。
- 配列番号10のアミノ酸配列を含むもしくはそれからなる重鎖定常領域、および/または、配列番号11のアミノ酸配列を含むもしくはそれからなる軽鎖定常領域を含む、請求項3または4に記載の抗体ポリペプチド。
- 配列番号12のアミノ酸配列を含むもしくはそれからなる重鎖、および/または、配列番号13のアミノ酸配列を含むもしくはそれからなる軽鎖を含む、請求項1〜5のいずれか1項に記載の抗体ポリペプチド。
- 抗体ポリペプチドが、直接または間接的に治療部分に連結されている、請求項1〜6のいずれか1項に記載の抗体ポリペプチド。
- 治療部分は、1つまたはそれ以上の放射性同位元素を含むまたはそれからなる細胞障害性部分である、請求項7に記載の抗体ポリペプチド。
- 1つまたはそれ以上の放射性同位元素は、β放射体、オージェ−放射体、転換電子放射体、α放射体および低光子エネルギー放射体からなる群からそれぞれ独立に選択される、請求項8に記載の抗体ポリペプチド。
- 1つもしくはそれ以上の放射性同位元素は、90Y、32P、186Re/188Re、166Ho、76As/77As、153Smのような長距離β放射体;131I、177Lu、67Cu、161Tbのような中距離β放射体;45Caまたは35Sまたは14Cのような低エネルギーβ放射体;51Cr、67Ga、99Tcm、111In、123I、125I、201Tlのような転換もしくはオージェ放射体;ならびに212Bi、213Bi、225Acおよび221Atのようなα放射体からなる群からそれぞれ独立に選択される、請求項9に記載の抗体ポリペプチド。
- 抗体ポリペプチドが、検出可能な部分をさらに含む、請求項1〜10のいずれか1項に記載のる抗体ポリペプチド。
- 検出可能な部分は、放射性同位元素を含むまたはそれからなる、請求項11に記載の抗体ポリペプチド。
- 放射性同位元素は、99mTc、111In、67Ga、68Ga、72As,89Zr、123Iおよび201Tlからなる群から選択される、請求項12に記載の抗体ポリペプチド。
- 治療部分および/または検出可能な部分は、連結部分を介して間接的に抗体ポリペプチドに繋がれている、請求項7〜13のいずれか1項に記載の抗体ポリペプチド。
- 連結部分は、1,4,7,10−テトラアザシクロドデカン−1,4,7,10四酢酸(DOTA)の誘導体、デフェロキサミン(DFO)、ジエチレントリアミン五酢酸(DTPA)の誘導体、S−2−(4−イソチオシアナトベンジル)−1,4,7−トリアザシクロノナン−1,4,7三酢酸(NOTA)の誘導体、および1,4,8,11−テトラアザシクロドデカン−1,4,8,11四酢酸(TETA)の誘導体からなる群から選択されるキレート化剤である、請求項14に記載の抗体ポリペプチド。
- 請求項1〜15のいずれか1項に記載の抗体ポリペプチド、またはそのポリペプチド鎖成分をコードする、単離された核酸分子。
- 配列番号14および/または配列番号15のヌクレオチド配列を含む、請求項16に記載の核酸分子。
- 請求項16または17に記載の核酸分子を含む、組換え宿主細胞。
- 請求項1〜15のいずれか1項に記載の抗体ポリペプチドおよび薬学的に許容できる賦形剤、希釈剤または担体を含む、医薬組成物。
- 医薬における使用のための、請求項1〜15のいずれか1項に記載の抗体ポリペプチド。
- 前立腺癌の治療および/または診断における使用のための、請求項1〜15のいずれか1項に記載の抗体ポリペプチド。
- 治療しようとする前立腺癌は、転移性前立腺癌、場合により微小転移性前立腺癌である、請求項21に記載の抗体ポリペプチド。
- 治療しようとする転移性前立腺癌は、リンパ系の転移;骨(脊椎、椎骨、骨盤、肋骨を含む)の転移;骨盤、直腸、膀胱、尿道内転移である、請求項22に記載の抗体ポリペプチド。
- 治療しようとする前立腺癌は、去勢抵抗性前立腺癌(CRPC)である、請求項21〜23のいずれか1項に記載の抗体ポリペプチド。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1320408.6 | 2013-11-19 | ||
GB1320408.6A GB2520353A (en) | 2013-11-19 | 2013-11-19 | Antibody polypeptides and uses thereof |
GB1401973.1 | 2014-02-05 | ||
GB201401973A GB201401973D0 (en) | 2014-02-05 | 2014-02-05 | Antibody polypeptides and uses thereof |
PCT/GB2014/053420 WO2015075445A1 (en) | 2013-11-19 | 2014-11-19 | Humanised anti kallikrein-2 antibody |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019181801A Division JP7051777B2 (ja) | 2013-11-19 | 2019-10-02 | ヒト化抗カリクレイン-2抗体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016540503A JP2016540503A (ja) | 2016-12-28 |
JP2016540503A5 true JP2016540503A5 (ja) | 2017-12-28 |
JP6599859B2 JP6599859B2 (ja) | 2019-10-30 |
Family
ID=52114029
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016532031A Active JP6599859B2 (ja) | 2013-11-19 | 2014-11-19 | ヒト化抗カリクレイン−2抗体 |
JP2019181801A Active JP7051777B2 (ja) | 2013-11-19 | 2019-10-02 | ヒト化抗カリクレイン-2抗体 |
JP2022003634A Pending JP2022062048A (ja) | 2013-11-19 | 2022-01-13 | ヒト化抗カリクレイン-2抗体 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019181801A Active JP7051777B2 (ja) | 2013-11-19 | 2019-10-02 | ヒト化抗カリクレイン-2抗体 |
JP2022003634A Pending JP2022062048A (ja) | 2013-11-19 | 2022-01-13 | ヒト化抗カリクレイン-2抗体 |
Country Status (22)
Country | Link |
---|---|
US (3) | US10100125B2 (ja) |
EP (2) | EP3553088A1 (ja) |
JP (3) | JP6599859B2 (ja) |
KR (3) | KR102574537B1 (ja) |
CN (2) | CN112898431B (ja) |
AU (3) | AU2014351611B2 (ja) |
BR (1) | BR112016011025B1 (ja) |
CA (1) | CA2930493A1 (ja) |
CY (1) | CY1121900T1 (ja) |
DK (1) | DK3071595T3 (ja) |
ES (1) | ES2728515T3 (ja) |
HR (1) | HRP20191095T1 (ja) |
HU (1) | HUE043875T2 (ja) |
IL (4) | IL311788A (ja) |
LT (1) | LT3071595T (ja) |
MX (2) | MX2016006561A (ja) |
PL (1) | PL3071595T3 (ja) |
PT (1) | PT3071595T (ja) |
RS (1) | RS58831B1 (ja) |
RU (1) | RU2687163C1 (ja) |
SI (1) | SI3071595T1 (ja) |
WO (1) | WO2015075445A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3071595T3 (da) * | 2013-11-19 | 2019-07-01 | Fredax Ab | Humaniseret anti-kallikrein-2-antistof |
BR112016022407A2 (pt) | 2014-03-28 | 2017-12-12 | Opko Diagnostics Llc | composições e métodos relacionados ao diagnóstico do câncer de próstata |
UA124522C2 (uk) | 2015-03-27 | 2021-10-05 | Опко Дайегностікс, Елелсі | Спосіб кількісної оцінки рівнів простатичного антигену |
US20180326102A1 (en) * | 2015-11-18 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods |
CA3045466A1 (en) | 2016-12-01 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
AU2018219909A1 (en) | 2017-02-10 | 2019-09-12 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-LAG3 antibodies for immuno-PET imaging |
KR102317805B1 (ko) * | 2017-03-30 | 2021-10-27 | 이씨에스-프로가스트린 에스에이 | 전립선암을 검출하기 위한 조성물 및 방법 |
BR112020001360A2 (pt) | 2017-07-24 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | anticorpo monoclonal isolado ou fragmento de ligação a antígeno deste que se liga a cd8, composição farmacêutica, molécula de ácido nucleico, vetor de expressão, célula hospedeira, conjugado de anticorpo, métodos para gerar imagens de um tecido que expressa cd8, para tratar um sujeito tendo um tumor sólido, para prever uma resposta positiva a uma terapia antitumoral, para monitorar uma resposta de um tumor em um sujeito a uma terapia antitumoral, para prever ou monitorar a eficácia da terapia antitumoral e para monitorar a presença de células t em um tumor ao longo do tempo, e, composto. |
AU2020273654A1 (en) | 2019-05-10 | 2021-11-25 | Janssen Biotech, Inc. | Macrocyclic chelators and methods of use thereof |
EP4004055A1 (en) * | 2019-07-26 | 2022-06-01 | Janssen Biotech, Inc. | Anti-hk2 chimeric antigen receptor (car) |
US20210040210A1 (en) * | 2019-07-26 | 2021-02-11 | Janssen Biotech, Inc. | Proteins Comprising Kallikrein Related Peptidase 2 Antigen Binding Domains And Their Uses |
US20220411504A1 (en) | 2020-05-27 | 2022-12-29 | Janssen Biotech, Inc. | Proteins comprising cd3 antigen binding domains and uses thereof |
EP4182353A1 (en) * | 2020-07-17 | 2023-05-24 | Janssen Biotech, Inc. | Anti-idiotypic antibodies against anti-klk2 antibodies |
AU2021379306A1 (en) * | 2020-11-10 | 2023-07-06 | Janssen Biotech, Inc. | Macrocyclic compounds and methods of use thereof |
CN112608365B (zh) * | 2020-12-22 | 2021-07-30 | 吉林省特医食品生物科技有限公司 | 一种减轻体重的发酵型小分子肽及其制备方法和应用 |
CN114790245A (zh) * | 2021-01-25 | 2022-07-26 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
EP4284446A2 (en) | 2021-01-27 | 2023-12-06 | Janssen Biotech, Inc. | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses |
US20230011134A1 (en) * | 2021-05-27 | 2023-01-12 | Janssen Biotech, Inc. | Compositions and methods for the treatment of prostate cancer |
CA3240194A1 (en) | 2021-11-09 | 2023-05-19 | Edward Cleator | Macrocyclic compounds and methods of making the same |
CA3236851A1 (en) | 2021-11-09 | 2023-05-19 | Janssen Biotech, Inc. | Macrocyclic compounds and diagnostic uses thereof |
WO2023144723A1 (en) | 2022-01-26 | 2023-08-03 | Janssen Biotech, Inc. | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
US5807978A (en) | 1995-06-07 | 1998-09-15 | Kokolus; William J. | Immunogenic peptides of prostate specific antigen |
US6379669B1 (en) | 1995-08-04 | 2002-04-30 | Akhouri A. Sinha | Targeting of organs by immunoconjugates |
CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
AU737659B2 (en) | 1996-11-14 | 2001-08-23 | Hybritech Incorporated | Method for detection of metastatic prostate cancer |
US7053042B1 (en) | 1999-07-29 | 2006-05-30 | Samuel Denmeade | Activation of peptide prodrugs by hK2 |
AU3879200A (en) | 1999-08-16 | 2001-03-13 | Zonagen, Inc. | Methods and materials for the treatment of prostatic carcinoma |
FI20002127A0 (fi) | 2000-09-27 | 2000-09-27 | Artic Partners Oy Ab | Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi |
WO2002098897A2 (en) | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
AU2002362447A1 (en) * | 2001-10-03 | 2003-04-14 | University Of Rochester | Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2 |
US8420353B2 (en) | 2002-03-22 | 2013-04-16 | Aprogen, Inc. | Humanized antibody and process for preparing same |
EP1596807A4 (en) | 2003-01-31 | 2008-05-21 | Albor Biolog Inc | IMMUNE REGULATION BASED ON TARGETING EARLY ACTIVATION MOLECULES |
EP1610818A4 (en) * | 2004-03-03 | 2007-09-19 | Millennium Pharm Inc | MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF |
CN101094869A (zh) * | 2004-08-03 | 2007-12-26 | 戴埃克斯有限公司 | Hk1结合蛋白 |
US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
US8663600B2 (en) | 2005-02-17 | 2014-03-04 | Diaprost Ab | Diagnosis of prostate cancer |
JP5249587B2 (ja) * | 2005-02-18 | 2013-07-31 | メダレックス, インク. | フコシル残基を欠く前立腺特異的膜抗原(psma)に対するモノクローナル抗体 |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
SG177168A1 (en) | 2006-12-01 | 2012-01-30 | Medarex Inc | Human antibodies that bind cd22 and uses thereof |
ES2560868T3 (es) * | 2006-12-22 | 2016-02-23 | Phadia Ab | Alérgeno de calicreína de próstata novedoso |
US20100261620A1 (en) | 2008-10-14 | 2010-10-14 | Juan Carlos Almagro | Methods of Humanizing and Affinity-Maturing Antibodies |
LT2771037T (lt) * | 2011-10-28 | 2017-01-25 | Fredax Ab | Terapiniai agentai ir jų panaudojimas |
DK3071595T3 (da) * | 2013-11-19 | 2019-07-01 | Fredax Ab | Humaniseret anti-kallikrein-2-antistof |
-
2014
- 2014-11-19 DK DK14814696.2T patent/DK3071595T3/da active
- 2014-11-19 EP EP19161698.6A patent/EP3553088A1/en active Pending
- 2014-11-19 KR KR1020227003223A patent/KR102574537B1/ko active IP Right Grant
- 2014-11-19 WO PCT/GB2014/053420 patent/WO2015075445A1/en active Application Filing
- 2014-11-19 CA CA2930493A patent/CA2930493A1/en active Pending
- 2014-11-19 CN CN202011566401.5A patent/CN112898431B/zh active Active
- 2014-11-19 MX MX2016006561A patent/MX2016006561A/es unknown
- 2014-11-19 HU HUE14814696A patent/HUE043875T2/hu unknown
- 2014-11-19 RU RU2016124229A patent/RU2687163C1/ru active
- 2014-11-19 PL PL14814696T patent/PL3071595T3/pl unknown
- 2014-11-19 JP JP2016532031A patent/JP6599859B2/ja active Active
- 2014-11-19 IL IL311788A patent/IL311788A/en unknown
- 2014-11-19 RS RS20190729A patent/RS58831B1/sr unknown
- 2014-11-19 IL IL297678A patent/IL297678B1/en unknown
- 2014-11-19 SI SI201431143T patent/SI3071595T1/sl unknown
- 2014-11-19 CN CN201480072422.8A patent/CN105980404B/zh active Active
- 2014-11-19 PT PT14814696T patent/PT3071595T/pt unknown
- 2014-11-19 BR BR112016011025-0A patent/BR112016011025B1/pt active IP Right Grant
- 2014-11-19 EP EP14814696.2A patent/EP3071595B1/en active Active
- 2014-11-19 LT LTEP14814696.2T patent/LT3071595T/lt unknown
- 2014-11-19 KR KR1020167016169A patent/KR102442738B1/ko active IP Right Grant
- 2014-11-19 AU AU2014351611A patent/AU2014351611B2/en active Active
- 2014-11-19 US US15/036,170 patent/US10100125B2/en active Active
- 2014-11-19 ES ES14814696T patent/ES2728515T3/es active Active
- 2014-11-19 KR KR1020237029468A patent/KR20230132599A/ko not_active Application Discontinuation
-
2016
- 2016-05-11 IL IL245617A patent/IL245617B/en active IP Right Grant
- 2016-05-19 MX MX2021007006A patent/MX2021007006A/es unknown
-
2018
- 2018-08-30 US US16/117,522 patent/US11230609B2/en active Active
-
2019
- 2019-06-17 HR HRP20191095TT patent/HRP20191095T1/hr unknown
- 2019-06-20 CY CY20191100645T patent/CY1121900T1/el unknown
- 2019-10-02 JP JP2019181801A patent/JP7051777B2/ja active Active
-
2020
- 2020-07-20 AU AU2020207775A patent/AU2020207775B2/en active Active
- 2020-11-04 IL IL278493A patent/IL278493B2/en unknown
-
2021
- 2021-09-16 US US17/476,683 patent/US20220064333A1/en active Pending
-
2022
- 2022-01-13 JP JP2022003634A patent/JP2022062048A/ja active Pending
-
2023
- 2023-08-30 AU AU2023222879A patent/AU2023222879A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016540503A5 (ja) | ||
JP7051777B2 (ja) | ヒト化抗カリクレイン-2抗体 | |
Kraeber-Bodéré et al. | Radioimmunoconjugates for the treatment of cancer | |
Kenanova et al. | Tailoring antibodies for radionuclide delivery | |
Sugiura et al. | Radiolabeling strategies for tumor-targeting proteinaceous drugs | |
JP2017532952A5 (ja) | ||
Navarro-Teulon et al. | General overview of radioimmunotherapy of solid tumors | |
Olafsen et al. | Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody | |
JP2019536442A5 (ja) | ||
JP2018527919A5 (ja) | ||
HRP20170879T1 (hr) | Genetski proizvodi koji su diferencijalno izraženi u tumorima i njihova primjena | |
Accardi et al. | Antibodies in single-chain format against tumour-associated antigens: present and future applications | |
JP2011501656A5 (ja) | ||
JP2014530898A5 (ja) | ||
JP2018532689A5 (ja) | ||
JP2018531045A5 (ja) | ||
GB2520353A (en) | Antibody polypeptides and uses thereof | |
RU2018115734A (ru) | Полипептиды антител и их применение | |
US8728477B2 (en) | Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof | |
Hauck et al. | Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia | |
JP2018531045A6 (ja) | 抗体ポリペプチド及びそれらの使用 | |
EP2193147B1 (en) | Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and use thereof | |
Sharma et al. | Evaluation of 177Lu-Labeled Pertuzumab F (ab′) 2 Fragments for HER2-Positive Cancer Targeting: A Comparative In Vitro and In Vivo Study | |
JPWO2010131590A1 (ja) | 腫瘍の診断剤又は治療剤 |